Home
About
Overview
Sharing Data
ORCID
Help
History (5)
False Positive Reactions
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Inhibition of junctional adhesion molecule-A/LFA interaction attenuates leukocyte trafficking and inflammation in brain ischemia/reperfusion injury.
Thoracoplasty
Treatment of hairy cell leukemia with recombinant alpha 2 interferon.
See All 5 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26):2473-83.
View in:
PubMed
subject areas
Adult
Aged
Aged, 80 and over
Angiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Bevacizumab
Carboplatin
Combined Modality Therapy
Disease-Free Survival
Double-Blind Method
Female
Humans
Middle Aged
Neoplasms, Glandular and Epithelial
Ovarian Neoplasms
Paclitaxel
Quality of Life
Survival Analysis
Young Adult
authors with profiles
Gini Fleming